You're listening to Plenary Session.

On this episode of Plenary Session, you're in for a treat.

I have listener feedback from the last episode of Plenary Session, where we talked about the rates of screening over time.

Next, I'm back in the thick of things. I'm back in Bill Cap.

Just when I thought I was out, you pulled me back in. I got to discuss it yet again.

Because the outcry about my treatment of Bill Cap is vociferous, loud, very nearly constant,

but unfortunately doesn't make solid points, and that's what I hope to convince you of.

Finally, I'm going to talk about waterfall plots in the medical journals over time.

We see a lot of waterfall plots.

They're often Instagrammed, hashtag no filtered, but what we find is they are in fact filtered.

They provide a visual distortion of the response rate.

And I'm going to take you through data done by

Sonny Kim that appears now in JAMA Network Open that proves this phenomenon is true. And finally,

I have a far-reaching discussion with Dr. Jeff Sharman, who is a community oncologist who's

known for running the hematology trials of the U.S. oncology group. He's done a lot of important clinical studies.

I had a slight mental lapse, and I forgot two things.

One, the approval of a sick inhibitor, two,

that Venetoclax had not been tested in DLBCL.

I knew these two things,

but yet I had these momentary lapses

because I had been busy working very, very hard on that Saturday.

So, forgive me those two things.

...